Shields RK - Search Results

Year	Number of Results
1945	1
1988	1
1992	2
1994	1
1995	2
1996	1
1997	5
1998	2
1999	2
2000	2
2001	1
2002	3
2003	1
2004	4
2005	9
2006	9
2007	4
2008	5
2009	6
2010	14
2011	19
2012	19
2013	15
2014	18
2015	12
2016	23
2017	23
2018	11
2019	21
2020	18
2021	21
2022	22
2023	25
2024	28
2025	19

1

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.

Shields RK, Paterson DL, Tamma PD. Shields RK, et al. Clin Infect Dis. 2023 May 1;76(Suppl 2):S179-S193. doi: 10.1093/cid/ciad094. Clin Infect Dis. 2023. PMID: 37125467 Free PMC article. Review.

2

The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative Meningitis.

Hsu AJ, Chiotos K, Heil EL, Shields RK, Tamma PD. Hsu AJ, et al. Among authors: shields rk. Clin Infect Dis. 2025 Jun 4;80(5):959-968. doi: 10.1093/cid/ciaf071. Clin Infect Dis. 2025. PMID: 39976357 Review.

3

Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.

Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Satola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, Pogue JM; PRECEDENT Network. Shields RK, et al. Lancet Infect Dis. 2025 May;25(5):574-584. doi: 10.1016/S1473-3099(24)00648-0. Epub 2024 Dec 16. Lancet Infect Dis. 2025. PMID: 39701120

4

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.

Timsit JF, Paul M, Shields RK, Echols R, Baba T, Yamano Y, Portsmouth S. Timsit JF, et al. Among authors: shields rk. Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078. Clin Infect Dis. 2022. PMID: 35148378 Free PMC article. Clinical Trial.

5

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. Shields RK, et al. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00883-17. doi: 10.1128/AAC.00883-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28559250 Free PMC article.

6

Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection.

Dorazio J, Chiappelli AL, Shields RK, Tsai YV, Skinker P, Nabozny MJ, Bauza G, Forsythe R, Rosengart MR, Gunn SR, Marini R, Clarke L, Falcione B, Ludwig J, McCreary EK. Dorazio J, et al. Among authors: shields rk. Open Forum Infect Dis. 2023 May 11;10(6):ofad258. doi: 10.1093/ofid/ofad258. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37351452 Free PMC article.

7

Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.

Shah S, Clarke LG, Ludwig J, Burgdorf S, Arbulu Guerra RD, Shields RK. Shah S, et al. Among authors: shields rk. J Antimicrob Chemother. 2024 Aug 1;79(8):1990-1997. doi: 10.1093/jac/dkae198. J Antimicrob Chemother. 2024. PMID: 38946294

8

Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.

Shah S, Kline EG, Haidar G, Squires KM, Pogue JM, McCreary EK, Ludwig J, Clarke LG, Stellfox M, Van Tyne D, Shields RK. Shah S, et al. Among authors: shields rk. Clin Infect Dis. 2025 Feb 5;80(1):24-28. doi: 10.1093/cid/ciae332. Clin Infect Dis. 2025. PMID: 38902935 Free PMC article.

9

Precision Rehabilitation: How Lifelong Healthy Behaviors Modulate Biology, Determine Health, and Affect Populations.

Shields RK. Shields RK. Phys Ther. 2022 Jan 1;102(1):pzab248. doi: 10.1093/ptj/pzab248. Phys Ther. 2022. PMID: 34718793 No abstract available.

10

Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections.

Shields RK, Dorazio AJ, Tiseo G, Squires KM, Leonildi A, Giordano C, Kline EG, Barnini S, Iovleva A, Griffith MP, Van Tyne D, Doi Y, Falcone M. Shields RK, et al. JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146. doi: 10.1093/jacamr/dlae146. eCollection 2024 Oct. JAC Antimicrob Resist. 2024. PMID: 39253335 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

327 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Results by year